Congenital CMV: Difference between revisions
From IDWiki
(→) |
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations") |
||
| Line 10: | Line 10: | ||
***'''Reactivation''': 1% risk |
***'''Reactivation''': 1% risk |
||
==Clinical |
==Clinical Manifestations== |
||
*Mother may have had asymptomatic infection |
*Mother may have had asymptomatic infection |
||
Revision as of 23:28, 14 July 2020
Epidemiology
- Maternal seroconversion in about 2% of pregnancies
- Higher in childcare workers
- Risk of transmission to fetus
- About 1 in 200 live births in US
- Primary infection: 30% risk of congenital CMV; higher risk later in pregnancy, but worse outcomes earlier
- Non-primary
- Reinfection: 5% risk
- Reactivation: 1% risk
Clinical Manifestations
- Mother may have had asymptomatic infection
- At birth
- Later
- Cognitive deficits (7%)
- Sensorineural hearing loss (20%)
Diagnosis
- In mom, IgM antibodies
- In baby, urine PCR within 2 weeks of birth
Management
- Treatment is indicated for symptomatic babies
- Brain
- Hearing
- Eye
- IV ganciclovir or PO valganciclovir, for 6 months
- Monitor CBC while on therapy
